In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy

PLoS One. 2017 Jul 21;12(7):e0181473. doi: 10.1371/journal.pone.0181473. eCollection 2017.

Abstract

Background: Absorbed doses for α-emitters are different from those for β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense energy deposition over a relatively short path length near the point of emission. This highly localized and therefore high energy deposition can lead to enhanced cell-killing effects at absorbed doses that are non-lethal in low-LET type of exposure. Affinities of DOTA-DPhe1-Tyr3-octreotate (DOTATATE), 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-DOTATATE were determined in the K562-SST2 cell line. Two other cell lines were used for radiation response assessment; BON and CA20948, with a low and high expression of somatostatin receptors, respectively. Cellular uptake kinetics of 111In-DOTATATE were determined in CA20948 cells. CA20948 and BON were irradiated with 137Cs, 177Lu-DTPA, 177Lu-DOTATATE, 213Bi-DTPA and 213Bi-DOTATATE. Absorbed doses were calculated using the MIRDcell dosimetry method for the specific binding and a Monte Carlo model of a cylindrical 6-well plate geometry for the exposure by the radioactive incubation medium. Absorbed doses were compared to conventional irradiation of cells with 137Cs and the relative biological effect (RBE) at 10% survival was calculated.

Results: IC50 of (labelled) DOTATATE was in the nM range. Absorbed doses up to 7 Gy were obtained by 5.2 MBq 213Bi-DOTATATE, in majority the dose was caused by α-particle radiation. Cellular internalization determined with 111In-DOTATATE showed a linear relation with incubation time. Cell survival after exposure of 213Bi-DTPA and 213Bi-DOTATATE to BON or CA20948 cells showed a linear-exponential relation with the absorbed dose, confirming the high LET character of 213Bi. The survival of CA20948 after exposure to 177Lu-DOTATATE and the reference 137Cs irradiation showed the typical curvature of the linear-quadratic model. 10% Cell survival of CA20948 was reached at 3 Gy with 213Bi-DOTATATE, a factor 6 lower than the 18 Gy found for 177Lu-DOTATATE and also below the 5 Gy after 137Cs external exposure.

Conclusion: 213Bi-DTPA and 213Bi-DOTATATE lead to a factor 6 advantage in cell killing compared to 177Lu-DOTATATE. The RBE at 10% survival by 213Bi-ligand compared to 137Cs was 2.0 whereas the RBE for 177Lu-DOTATATE was 0.3 in the CA20948 in vitro model.

Publication types

  • Comparative Study

MeSH terms

  • Absorption, Radiation*
  • Bismuth*
  • Cell Line, Tumor
  • Cell Survival / radiation effects
  • Dose-Response Relationship, Radiation
  • Humans
  • Kinetics
  • Linear Energy Transfer
  • Lutetium*
  • Models, Biological
  • Monte Carlo Method
  • Octreotide / analogs & derivatives*
  • Octreotide / pharmacology*
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / pharmacology
  • Radioisotopes* / administration & dosage
  • Radioisotopes* / pharmacokinetics
  • Radiometry
  • Radiopharmaceuticals* / administration & dosage
  • Radiopharmaceuticals* / pharmacokinetics
  • Receptors, Somatostatin / metabolism*

Substances

  • Organometallic Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • SSTR2 protein, human
  • Lutetium
  • Octreotide
  • Bismuth

Grants and funding

This research was supported by the Dinse Stiftung. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.